Skip to main content
Premium Trial:

Request an Annual Quote

Warnex Receives Funding for 'Touch DNA' Analysis

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Canadian life science firm Warnex today announced it will receive up to C$47,300 ($47,000) for analysis of "Touch DNA" samples from used firearm cartridges.

The company also announced that one of its divisions has received accreditation from the American Society of Crime Lab Directors/Laboratory Accreditation Board-International.

The funding comes as a result of the signing of a contribution agreement between the Laval, Quebec-based firm and the National Research Council of Canada's Industrial Research Assistance Program, which will also provide technical and business advisory services.

Research will be carried out at Warnex's PRO-DNA Services division in Thunder Bay, Ontario.

Touch DNA refers to DNA analysis of skin cells left on an object. Because the amount of DNA is in very small trace amounts, analyzing it has been a challenge. Warnex will use nuclear and mitochondrial DNA methods to improve the analysis of Touch DNA samples, it said in a statement.

Separately, the company said today that the PRO-DNA Services division has received accreditation from the American Society of Crime Lab Directors/Laboratory Accreditation Board-International. The division received accreditation specifically for the categories of nuclear and mitochondrial DNA testing, relationship testing, and body fluid identification.

Warnex said it is the only private laboratory in Canada that provides STR, Y-STR, miniSTR, and mitochondrial DNA testing for forensic and parentage purposes.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more